← feed

Is NCT03184168 results overdue?

Yes — results are overdue. Primary completion was 2017-08-07; the FDAAA-801 reporting deadline (2018-08-07) passed 2875 days ago and no results are posted on ClinicalTrials.gov.

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

NCT IDNCT03184168 ↗
SponsorPfizer (INDUSTRY)
Public issuerPFIZER INC — PFE (CIK 0000078003) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-08-07 (ACTUAL)
Reporting deadline2018-08-07 (completion + 365d)
Days overdue2875
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 01a50e966913d507… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03184168. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →